Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat breast cancer: phase 3 trial targets genetic driver

NCT ID NCT05038735

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding the drug alpelisib to standard fulvestrant treatment helps control advanced breast cancer better than fulvestrant alone. It is for men and postmenopausal women whose cancer has a specific genetic change (PIK3CA mutation) and has worsened after previous hormone therapy and a CDK4/6 inhibitor drug. The main goal is to see if the combination slows cancer growth for a longer time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Sint-Niklaas, Oost Vlaanderen, 9100, Belgium

  • Novartis Investigative Site

    Brussels, 1000, Belgium

  • Novartis Investigative Site

    Brussels, 1200, Belgium

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    Leuven, 3000, Belgium

  • Novartis Investigative Site

    Liège, 4000, Belgium

  • Novartis Investigative Site

    Plovdiv, 4004, Bulgaria

  • Novartis Investigative Site

    Sofia, 1330, Bulgaria

  • Novartis Investigative Site

    Calgary, Alberta, T2N 5G2, Canada

  • Novartis Investigative Site

    Ottawa, Ontario, K1H 8L6, Canada

  • Novartis Investigative Site

    Brno, 656 53, Czechia

  • Novartis Investigative Site

    Nový Jičín, 741 01, Czechia

  • Novartis Investigative Site

    Prague, 100 34, Czechia

  • Novartis Investigative Site

    Prague, 128 08, Czechia

  • Novartis Investigative Site

    Prague, 140 59, Czechia

  • Novartis Investigative Site

    Aalborg, 9000, Denmark

  • Novartis Investigative Site

    Helsinki, 00029, Finland

  • Novartis Investigative Site

    Tampere, FIN-33521, Finland

  • Novartis Investigative Site

    Besançon, 25030, France

  • Novartis Investigative Site

    Clermont-Ferrand, 63011, France

  • Novartis Investigative Site

    La Roche-sur-Yon, 85925, France

  • Novartis Investigative Site

    Lyon, 69373, France

  • Novartis Investigative Site

    Marseille, 13273, France

  • Novartis Investigative Site

    Montpellier, 34298, France

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Paris, 75970, France

  • Novartis Investigative Site

    Valenciennes, 59300, France

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    Augsburg, 86150, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Essen, 45136, Germany

  • Novartis Investigative Site

    Lübeck, 23538, Germany

  • Novartis Investigative Site

    Athens, 115 22, Greece

  • Novartis Investigative Site

    Pátrai, 265 04, Greece

  • Novartis Investigative Site

    Budapest, H 1122, Hungary

  • Novartis Investigative Site

    Dublin, DO4, Ireland

  • Novartis Investigative Site

    Bari, BA, 70124, Italy

  • Novartis Investigative Site

    Bergamo, BG, 24127, Italy

  • Novartis Investigative Site

    Bologna, BO, 40138, Italy

  • Novartis Investigative Site

    Florence, FI, 50134, Italy

  • Novartis Investigative Site

    Genova, GE, 16132, Italy

  • Novartis Investigative Site

    Milan, MI, 20132, Italy

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    Milan, MI, 20141, Italy

  • Novartis Investigative Site

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    Palermo, PA, 90127, Italy

  • Novartis Investigative Site

    Padua, PD, 35128, Italy

  • Novartis Investigative Site

    Aviano, PN, 33081, Italy

  • Novartis Investigative Site

    Roma, RM, 00168, Italy

  • Novartis Investigative Site

    Terni, TR, 05100, Italy

  • Novartis Investigative Site

    Napoli, 80131, Italy

  • Novartis Investigative Site

    Bydgoszcz, 85 796, Poland

  • Novartis Investigative Site

    Coimbra, 3000-075, Portugal

  • Novartis Investigative Site

    Lisbon, 1099-023, Portugal

  • Novartis Investigative Site

    Lisbon, 1400-038, Portugal

  • Novartis Investigative Site

    Porto, 4200-072, Portugal

  • Novartis Investigative Site

    Floreşti, Cluj, 407280, Romania

  • Novartis Investigative Site

    Bratislava, 812 50, Slovakia

  • Novartis Investigative Site

    Bratislava, 83310, Slovakia

  • Novartis Investigative Site

    Košice, 041 91, Slovakia

  • Novartis Investigative Site

    Badajoz, Extremadura, 06080, Spain

  • Novartis Investigative Site

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Novartis Investigative Site

    Oviedo, Principality of Asturias, 33011, Spain

  • Novartis Investigative Site

    A Coruña, 15009, Spain

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Madrid, 28040, Spain

  • Novartis Investigative Site

    Málaga, 29011, Spain

  • Novartis Investigative Site

    Zaragoza, 50009, Spain

Conditions

Explore the condition pages connected to this study.

BREAST CANCER